drugset / Trial / NCT04943900
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Timeline
- Start
- 2021-08-09
- Primary completion
- 2025-02-27
- Completion
- 2025-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986416 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |